Dysregulation of peptide-activated pathways causes a range of diseases, fostering the
discovery and clinical development of peptide drugs. Many endogenous peptides activate G …

Apelin and its G protein-coupled receptor (GPCR) have emerged as a key signalling
pathway in the cardiovascular system. The peptide is a potent inotropic agent and …

Apelin peptides mediate beneficial effects on the cardiovascular system and are being
targeted as potential new drugs. However, apelin peptides have extremely short biological …

ELABELA (ELA) was recently discovered as a novel endogenous ligand of the apelin
receptor (APJ), a G protein-coupled receptor. ELA signaling was demonstrated to be crucial …

Apelin and apela (ELABELA/ELA/Toddler) are two peptide ligands for a class A G-protein-
coupled receptor named the apelin receptor (AR/APJ/APLNR). Ligand-AR interactions have …

The apelin/apelin receptor system is widely distributed and has a dominant role in
cardiovascular homeostasis and disease. The apelin gene is X-linked and is synthesized as …

Apelin is an endogenous peptide ligand for the G protein-coupled receptor
APJ/AGTRL1/APLNR and is widely expressed throughout human body. In adult hearts …

The apelinergic pathway has been generating increasing interest in the past few years for its
potential as a therapeutic target in several conditions associated with the cardiovascular and …

The G protein-coupled receptor APJ and its cognate ligand, apelin, are widely expressed
throughout human body. They are implicated in different key physiological processes such …

The discovery of apelin, an endogenous ligand of the orphan APJ receptor is an important
advance for fundamental research and clinical medicine. Apelin and its receptor have a …